CL2023000261A1 - Métodos de tratamiento de la neuralgia del trigémino - Google Patents

Métodos de tratamiento de la neuralgia del trigémino

Info

Publication number
CL2023000261A1
CL2023000261A1 CL2023000261A CL2023000261A CL2023000261A1 CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1 CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1
Authority
CL
Chile
Prior art keywords
trigeminal neuralgia
treatment methods
neuralgia treatment
subject
methods
Prior art date
Application number
CL2023000261A
Other languages
English (en)
Spanish (es)
Inventor
Garibaldi George
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of CL2023000261A1 publication Critical patent/CL2023000261A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CL2023000261A 2020-07-30 2023-01-26 Métodos de tratamiento de la neuralgia del trigémino CL2023000261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30

Publications (1)

Publication Number Publication Date
CL2023000261A1 true CL2023000261A1 (es) 2023-09-08

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000261A CL2023000261A1 (es) 2020-07-30 2023-01-26 Métodos de tratamiento de la neuralgia del trigémino

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2011035209A1 (en) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Also Published As

Publication number Publication date
TW202220649A (zh) 2022-06-01
EP4188370A1 (en) 2023-06-07
CN115989024A (zh) 2023-04-18
AU2021316675A1 (en) 2023-01-19
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
BR112023001621A2 (pt) 2023-04-04
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2020001945A1 (es) Compuestos.
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2020004249A2 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
CL2017002693A1 (es) Métodos para tratar infecciones por el virus filoviridae. divisional de solicitud n° 1040-2017.
UY36702A (es) Piridinas sustituidas y métodos de uso
UY37706A (es) Compuestos antitumorales
CL2023000594A1 (es) Compuestos heterocíclicos
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
MY207276A (en) Modulators of trex1
NI202000062A (es) Régimen posológico del modulador del ensamblaje de la cápside
MX2021015572A (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
AR108344A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORgT
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2022003435A1 (es) Métodos de tratamiento del complejo de esclerosis tuberosa
MY193946A (en) Functionalised polysulphide synthesis method
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
CL2023000261A1 (es) Métodos de tratamiento de la neuralgia del trigémino
MX2022008016A (es) Compuesto antagonista de pd-l1.